Nurix Therapeutics, Inc. (NRIX): who owns it and who trades it
As of Nov 16, 2026, NRIX insiders reported 45 open-market sales worth $5.6M and no purchases in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christine Ring (Chief Legal Officer), with $3.8M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Nurix Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NRIX
212 funds and institutions reported NRIX shares worth $2.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 8.77M | 8.45% | $213M | -2% |
| Vestal Point Capital, LP | 8.05M | 7.76% | $195M | +24% |
| Deep Track Capital, LP | 7.74M | 7.45% | $188M | +22% |
| Rubric Capital Management LP | 7.23M | 6.96% | $175M | +192% |
| FMR LLC (Fidelity) | 5.49M | 5.29% | $133M | -1% |
| T. Rowe Price Associates | 5.44M | 5.24% | $132M | +65% |
| Morgan Stanley | 4.76M | 4.59% | $116M | -3% |
| State Street Corp | 4.68M | 4.51% | $113M | -9% |
| Baker Bros. Advisors LP | 4.66M | 4.49% | $113M | No change |
| Vanguard Capital Management LLC | 4.50M | 4.33% | $109M | +2% |
| Perceptive Advisors LLC | 4.32M | 4.16% | $105M | +16% |
| Redmile Group, LLC | 4.07M | 3.93% | $98.8M | -47% |
| General Atlantic, L.P. | 3.03M | 2.92% | $73.6M | -26% |
| Geode Capital Management, LLC | 2.54M | 2.44% | $61.6M | +1% |
| Pictet Asset Management Holding SA | 2.35M | 2.27% | $57M | -14% |
| ARK Investment Management LLC | 1.79M | 1.73% | $43.5M | +4% |
| Capital World Investors | 1.79M | 1.72% | $43.4M | +100% |
| California State Teachers Retirement System | 1.68M | 1.62% | $69.3M | +1598% |
| Trails Edge Capital Partners, LP | 1.57M | 1.52% | $38.2M | -10% |
| Vanguard Portfolio Management LLC | 1.48M | 1.43% | $36M | +35% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NRIX insiders reported $0 of open-market purchases and $5.6M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Houte Hans van | CFO | Sale plan | 3,300 | $15.38 | $50.8K | Form 4 |
| Nov 4, 2026 | Houte Hans van | CFO | Sale plan | 1,469 | $16.20 | $23.8K | Form 4 |
| Nov 3, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 6,113 | $25.83 | $158K | Form 4 |
| Nov 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 9,527 | $25.74 | $245K | Form 4 |
| Nov 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 1,075 | $26.76 | $28.8K | Form 4 |
| Nov 2, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 1,452 | $26.80 | $38.9K | Form 4 |
| Oct 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 3,957 | $26.28 | $104K | Form 4 |
| Oct 30, 2026 | Houte Hans van | CFO | Sale | 2,834 | $26.28 | $74.5K | Form 4 |
| Oct 15, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 1,452 | $25.00 | $36.3K | Form 4 |
| Oct 14, 2026 | Julia P Gregory | Director | Sale | 22,583 | $23.40 | $529K | Form 4 |
| Oct 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 5,786 | $23.19 | $134K | Form 4 |
| Sep 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 400 | $26.64 | $10.7K | Form 4 |
| Sep 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 5,387 | $25.69 | $138K | Form 4 |
| Sep 1, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 1,452 | $25.47 | $37K | Form 4 |
| Aug 5, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 4,356 | $25.00 | $109K | Form 4 |
| Aug 4, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 2,611 | $24.64 | $64.3K | Form 4 |
| Aug 4, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 1,500 | $23.87 | $35.8K | Form 4 |
| Aug 4, 2026 | Houte Hans van | CFO | Sale plan | 1,794 | $23.89 | $42.9K | Form 4 |
| Aug 4, 2026 | Houte Hans van | CFO | Sale plan | 2,967 | $24.65 | $73.1K | Form 4 |
| Aug 3, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 16,589 | $23.05 | $382K | Form 4 |
| Jul 30, 2026 | Houte Hans van | CFO | Sale | 2,845 | $23.38 | $66.5K | Form 4 |
| Jul 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 3,847 | $23.38 | $89.9K | Form 4 |
| Jul 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 11,008 | $23.56 | $259K | Form 4 |
| Jun 25, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale plan | 5,394 | $20.00 | $108K | Form 4 |
| Jun 25, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 28,935 | $20.06 | $580K | Form 4 |
| Jun 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 8,148 | $16.60 | $135K | Form 4 |
| May 5, 2026 | Houte Hans van | CFO | Sale plan | 582 | $17.18 | $10K | Form 4 |
| May 5, 2026 | Houte Hans van | CFO | Sale plan | 13,473 | $16.58 | $223K | Form 4 |
| May 4, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 8,148 | $16.96 | $138K | Form 4 |
| May 1, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 5,394 | $16.76 | $90.4K | Form 4 |
| Apr 30, 2026 | Houte Hans van | CFO | Sale | 2,388 | $16.65 | $39.8K | Form 4 |
| Apr 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 3,214 | $16.65 | $53.5K | Form 4 |
| Apr 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 8,148 | $15.24 | $124K | Form 4 |
| Mar 2, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 8,148 | $15.44 | $126K | Form 4 |
| Feb 9, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 14,261 | $16.66 | $238K | Form 4 |
| Jan 30, 2026 | Houte Hans van | CFO | Sale | 73 | $17.37 | $1.3K | Form 4 |
| Jan 30, 2026 | Houte Hans van | CFO | Sale | 3,588 | $16.58 | $59.5K | Form 4 |
| Jan 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 88 | $17.37 | $1.5K | Form 4 |
| Jan 30, 2026 | Christine Ring | Chief Legal Officer | Sale | 4,333 | $16.58 | $71.8K | Form 4 |
| Jan 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 98 | $17.37 | $1.7K | Form 4 |
| Jan 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sale | 4,797 | $16.58 | $79.5K | Form 4 |
| Jan 20, 2026 | Christine Ring | Chief Legal Officer | Sale plan | 3,760 | $18.42 | $69.3K | Form 4 |
| Dec 18, 2025 | Christine Ring | Chief Legal Officer | Sale plan | 3,560 | $17.87 | $63.6K | Form 4 |
| Dec 18, 2025 | Christine Ring | Chief Legal Officer | Sale plan | 200 | $18.56 | $3.7K | Form 4 |
| Nov 24, 2025 | Christine Ring | Chief Legal Officer | Sale plan | 37,600 | $17.07 | $642K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Christine Ring | Chief Legal Officer | – | $3.8M | Nov 3, 2026 |
| Houte Hans van | Chief Financial Officer | – | $665K | Nov 4, 2026 |
| Gwenn Hansen | Chief Scientific Officer | – | $614K | Nov 2, 2026 |
| Julia P Gregory | Director | – | $529K | Oct 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NRIX short interest
High short interest. 17.3% of NRIX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.94M NRIX shares were sold short, 17.3% of the shares outstanding, down 8.1% from the report before. At the average daily volume of 2.64M shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.94M | 17.33% | -8% | 2.64M | 7.2 |
| Oct 15, 2026 | 20.61M | 18.86% | +17% | 2.24M | 9.2 |
| Sep 30, 2026 | 17.66M | 16.16% | -2% | 1.78M | 9.9 |
| Sep 15, 2026 | 17.98M | 17.32% | +0% | 1.28M | 14.1 |
| Aug 31, 2026 | 17.95M | 17.30% | -0% | 1.13M | 15.9 |
| Aug 14, 2026 | 17.98M | 17.33% | -2% | 993,103 | 18.1 |
| Jul 31, 2026 | 18.35M | 17.68% | +2% | 1.02M | 18.0 |
| Jul 15, 2026 | 17.98M | 17.32% | +1% | 1.30M | 13.9 |
| Jun 30, 2026 | 17.80M | 17.15% | -11% | 3.28M | 5.4 |
| Jun 15, 2026 | 20.02M | 19.37% | +4% | 4.05M | 4.9 |
| May 29, 2026 | 19.32M | 18.69% | +4% | 1.30M | 14.9 |
| May 15, 2026 | 18.63M | 18.02% | -3% | 838,931 | 22.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Nurix Therapeutics company events
Nurix Therapeutics filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026AnnouncementNurix Therapeutics, Inc. announced that collaboration partner Sanofi S.A. had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. Filing
- Oct 13, 2026ResultsReleased financial results. Filing
- Jul 9, 2026ResultsReleased financial results. Filing
- Jun 11, 2026AnnouncementThe Company announced updated data from the Phase 1 clinical trial of bexobrutideg (NX-5948). Filing
- Jun 8, 2026AgreementNurix Therapeutics, Inc. entered into a License and Collaboration Agreement, dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “ Roche ”), pursuant to which Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its… Filing
- May 15, 2026VoteReported shareholder vote results. Filing
- Apr 8, 2026ResultsReleased financial results. Filing
- Mar 6, 2026AnnouncementAs previously disclosed, on August 4, 2021, Nurix Therapeutics, Inc., a Delaware corporation, entered into an equity distribution agreement with Piper Sandler & Co., which Equity Distribution Agreement was subsequently amended by Amendment No. 1 to the Equity Distribution Agreement on July 11, 2024… Filing
- Jan 28, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 9, 2025AnnouncementThe Company announced new clinical data from the Phase 1a/1b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory CLL and SLL, and on December 8, 2025, the Company announced new clinical data from patients with relapsed or refractory Waldenström macroglobulinemia (WM)… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Nurix Therapeutics financials
Famous investors that hold NRIX
5 of the 50 well-known investors we track reported holding NRIX in their latest 13F filing. The largest position is Cathie Wood's, worth $43.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 1.85M | $43.9M | 0.3% | +3% |
| Israel Englander · Millennium Management | Q3 2026 | 412,768 | $9.8M | 0.0% | +1874% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 356,843 | $8.5M | 0.0% | -3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 164,201 | $3.9M | 0.0% | -89% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 51,588 | $1.2M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named NRIX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Deep Track Capital, LP | 13G/A | 5.5% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.4% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 6.4% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 4.5% |
| Nov 16, 2026 | Deep Track Capital, LP | 13G/A | 5.5% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 4.9% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 4.9% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.4% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 4.5% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 6.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 4.2% |
| Nov 5, 2026 | FMR LLC | 13G/A | 4.2% |
Questions about Nurix Therapeutics, Inc. (NRIX) stock
Who owns the most NRIX stock?
The largest reported owner of Nurix Therapeutics, Inc. (NRIX) is BlackRock, Inc., with 8.5% of the company. In total, 212 funds and institutions reported holding NRIX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are NRIX insiders buying or selling?
In the last 12 months, NRIX insiders reported no open-market purchases and 45 sales worth $5.6M. The latest trade was on Nov 4, 2026. See every trade.
What is the short interest in NRIX?
As of Oct 30, 2026, 18.94M NRIX shares were sold short, 17.3% of the shares outstanding, down 8.1% from the report before. At the average daily volume of 2.64M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Which famous investors hold NRIX?
5 of the 50 well-known investors we track reported NRIX in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Fisher. The largest position is worth $43.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.